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Background-—Options for interventional therapy to lower blood pressure (BP) in patients with treatment-resistant hypertension
include renal denervation and the creation of an arteriovenous anastomosis using the ROX coupler. It has been shown that BP
response after renal denervation is greater in patients with combined hypertension (CH) than in patients with isolated systolic
hypertension (ISH). We analyzed the effect of ROX coupler implantation in patients with CH as compared with ISH.
Methods and Results-—The randomized, controlled, prospective ROX Control Hypertension Study included patients with true
treatment-resistant hypertension (ofﬁce systolic BP ≥140 mm Hg, average daytime ambulatory BP ≥135/85 mm Hg, and
treatment with ≥3 antihypertensive drugs including a diuretic). In a post hoc analysis, we stratiﬁed patients with CH (n=31) and ISH
(n=11). Baseline ofﬁce systolic BP (17718 mm Hg versus 16917 mm Hg, P=0.163) and 24-hour ambulatory systolic BP
(15916 mm Hg versus 15411 mm Hg, P=0.463) did not differ between patients with CH and those with ISH. ROX coupler
implementation resulted in a signiﬁcant reduction in ofﬁce systolic BP (CH: 2921 mm Hg versus ISH: 2231 mm Hg,
P=0.445) and 24-hour ambulatory systolic BP (CH: 1420 mm Hg versus ISH: 1315 mm Hg, P=0.672), without signiﬁcant
differences between the two groups. The responder rate (ofﬁce systolic BP reduction ≥10 mm Hg) after 6 months was not
different (CH: 81% versus ISH: 82%, P=0.932).
Conclusions-—Our data suggest that creation of an arteriovenous anastomosis using the ROX coupler system leads to a similar
reduction of ofﬁce and 24-hour ambulatory systolic BP in patients with combined and isolated systolic hypertension.
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A rterial hypertension is the most prevalent and majormodiﬁable risk factor for cardiovascular morbidity and
mortality worldwide.1 Although several effective and safe antihy-
pertensive drug classes are available, the prevalence rate of
treatment-resistant hypertension (TRH) remains 8% to 15%.2,3
Moreover, it has been reported that within a median of 1.5 years
after initiation of antihypertensive treatment, 1 of 50 patients
develops TRH.4 This is of crucial importance, since the diagnosis
of TRH carries signiﬁcantly greater cardiovascular risk compared
with patients without TRH.5,6 Therefore, innovative therapeutic
strategies are needed to achieve blood pressure (BP) control and
reduction of cardiovascular mortality in this population.
Several interventional approaches for lowering BP in patients
with TRH have recently been introduced. Most depend on
modulation of sympathetic activity, for example through renal
denervation (RDN) or baroreﬂex activation. However, the BP
response to RDN is markedly heterogeneous and it is not fully
known whether this is due to technical failure or a diminished
role of renal sympathetic signaling in nonresponders.7–9 It has
been suggested that the effect of reduced sympathetic activity
(due to RDN), and hence the potential to decrease BP in the short
term may be limited in patients with advanced vascular
remodeling.10 Furthermore, in patients with isolated systolic
hypertension (ISH) (ofﬁce BP ≥140 mm Hg systolic and
<90 mm Hg diastolic), indicative of arterial stiffness, BP reduc-
tion due to RDN was attenuated compared with patients with
combined hypertension (CH) (ofﬁce BP ≥140/≥90 mm Hg).11
Thiswas conﬁrmed in a post hoc analysis of pooled data from the
Symplicity HTN-3 trial and theGlobal SYMPLICITY Registry. Even
though patients with ISH had a reduction in systolic BP (SBP)
6 months after RDN, the magnitude of SBP reduction was less
pronounced than that seen in patients with CH.12
An alternative approach to nonpharmacological BP reduction
targeting mechanical aspects of the circulation is the percuta-
neouscreation of a therapeutic arteriovenous anastomosis using
the ROX coupler system, thereby increasing arterial compliance
and reducing total peripheral resistance.13 In the randomized
controlled ROX Control Hypertension Study (NCT01642498), a
central iliac arteriovenous anastomosis resulted in signiﬁcant
reductions in both ofﬁce and 24-hour ambulatory BP (ABP)
compared with medically managed patients.14
The aim of the current post hoc analysis was to assess the
effects of ROX coupler implantation on ofﬁce and 24-hour
ABP in patients with CH compared with patients with ISH
using data from the ROX Control Hypertension Study.
Methods
Study Design and Cohort
The ROX Control Hypertension Study was conducted between
October 2012 and April 2014, and its design has been
published elsewhere.14 In brief, the study was a European,
open-label, multicenter, prospective, randomized, controlled
trial assessing the safety and efﬁcacy of an arteriovenous
anastomosis for BP-lowering purposes in patients with TRH.
Inclusion criteria were age between 18 and 80 years and
presence of TRH (ofﬁce SBP ≥140 mm Hg and average
daytime ABP ≥135/85 mm Hg despite treatment with at
least 3 antihypertensive drugs including a diuretic) on a stable
drug regimen (without change in dose or medication) for at
least 2 weeks. Exclusion criteria were secondary hyperten-
sion other than sleep apnea, RDN within the previous
6 months, an estimated glomerular ﬁltration rate (eGFR)
<30 mL/min per 1.73 m2 and type 1 diabetes, current
diagnosis of unstable cardiac disease requiring intervention,
history of heart failure, recent myocardial infarction, unstable
angina, coronary angioplasty or bypass surgery within last
6 months, current severe cerebrovascular disease or stroke
within the previous year, and signiﬁcant peripheral arterial or
venous disease. Furthermore, patients in the intervention
group with pulmonary arterial hypertension (mean pulmonary
artery pressure >25 mm Hg) and/or elevated pulmonary
capillary wedge pressure (>15 mm Hg) were excluded.
Patients were randomly (stratiﬁed by study site and previous
treatment with RDN) assigned to intervention (percutaneous
creation of an arteriovenous anastomosis) plus continuation of
antihypertensive medication or maintenance of antihyperten-
sivemediation alone in a 1:1 fashion. However, for this post hoc
analysis, only patients who were randomized to ROX coupler
implementation and were not lost to follow-up were included.
The study was approved by the ethics committees of the
participating centers and was performed according to the
Declaration of Helsinki and Good Clinical Practice guidelines.
Written informed consent was obtained from all patients before
study entry. The study was registered at www.clinicaltrials.gov
(ID: NCT01642498).
Creation of an Arteriovenous Anastomosis
The procedure for creation of an arteriovenous anastomosis is
described in detail elsewhere.14 In brief, the placement of the
ROX coupler creates a ﬁxed caliber 4-mm arteriovenous
anastomosis between the distal external iliac artery and vein
in a standard cardiovascular catheterization laboratory setting
under ﬂuoroscopic guidance. The self-expanding nitinol device
permits a controlled shunt volume of 800 to 1000 mL/min.15
Use of anticoagulation was determined on an individual basis
by the interventionalist.
Ofﬁce and 24-Hour ABP Monitoring
Ofﬁce BP was measured according to standard recommen-
dations in the nondominant arm, and the average of 3
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measurements was taken. If BP values were more than
15 mm Hg apart, measurements were repeated and the
means of the last 3 consecutive consistent readings were
taken. ABP measurements were performed with validated
automatic portable devices. Readings were taken every
30 minutes during daytime and every 60 minutes during
nighttime. Measurements were deemed acceptable if there
were at least 70% successful readings over 24 hours or if 14
successful readings during daytime and 7 during nighttime
were recorded. Patients were graded according to their
dipping pattern into dippers (nighttime BP fall ≥10%) and
nondippers (nighttime BP fall <10%).
A responder was deﬁned as a patient with ofﬁce SBP
reduction ≥10 mm Hg 6 months after intervention.
Statistical Analysis
All analyses were performed using IBM SPSS Statistics for
Windows, version 21.0 (IBM Corp., Armonk, NY). Following our
hypothesis, patients were categorized into CH or ISH groups
according to their baseline ofﬁce BP. Data were compared by
paired and unpaired Student t tests, Wilcoxon and McNemar
tests, and Fisher exact test as appropriate, and were
presented as meanSD in the text and meanSEM in the
ﬁgures, respectively. A general linear model was used to
assess interaction and adjust for possible inﬂuencing factors
between the two groups. A 2-sided P value of <0.05 was
considered statistically signiﬁcant.
Results
Baseline characteristics of patients stratiﬁed according to
type of hypertension (CH [n=31] versus ISH [n=11]) are given
in Table 1. Ofﬁce SBP and 24-hour systolic ABP were higher in
patients with CH compared with those with ISH, but the
difference did not reach statistical signiﬁcance. Per deﬁnition,
ofﬁce diastolic BP (DBP) and 24-hour diastolic ABP were
higher in patients with CH compared with those with ISH.
There was no difference in the number of patients with prior
RDN between the two groups (P=0.372).
Ofﬁce BP
There was a signiﬁcant reduction of ofﬁce SBP and DBP after
6 months by 2921/2413 mm Hg (both P<0.001) in
the CH group and by 2231/1013 mm Hg (both
P<0.05) in the ISH group. Most importantly, the change in
ofﬁce SBP did not signiﬁcantly differ between the two groups
(P=0.445) (Figure 1). The general linear model did not reveal
an interaction between baseline ofﬁce SBP and type of
hypertension (P=0.226). After adjusting for baseline ofﬁce
SBP, there was no difference in ofﬁce SBP reduction
6 months after ROX coupler implementation between the
two groups (P=0.991). Even after full adjustment (sex, age,
and ofﬁce SBP and DBP), no difference in ofﬁce SBP reduction
was detected (P=0.669).
Responder Rate
A total of 25 patients in the CH group (81%) and 9 patients in
the ISH group (82%) had an ofﬁce SBP reduction ≥10 mm Hg
(usually deﬁned as a BP responder after an interventional
strategy of BP lowering), which was not signiﬁcantly different
(P=0.932).
Table 1. Clinical Characteristics of Patients Stratiﬁed
According to Subtype of Hypertension Into CH and ISH
CH (n=31) ISH (n=11) P Value
Age, y 58.410 63.16 0.110
Male/female 22/9 10/1 0.182
Body mass index, kg/m2 30.03.4 31.04.8 0.571
Office blood pressure
Systolic, mm Hg 17718 16917 0.163
Diastolic, mm Hg 10612 872 <0.001
Pulse pressure, mm Hg 7215 8217 0.092
Ambulatory blood pressure
Systolic, mm Hg 15916 15411 0.463
Diastolic, mm Hg 9512 867 0.019
Pulse pressure, mm Hg 6311 6811 0.172
eGFR, mL/min per 1.73 m2 79.120 67.819 0.163
CH indicates combined hypertension; eGFR, estimated glomerular ﬁltration rate; ISH,
isolated systolic hypertension.
Figure 1. Change in ofﬁce systolic and diastolic blood pressure
(BP) 6 months after ROX coupler implementation in the combined
hypertension group (black columns) vs in the isolated systolic
hypertension group (white columns).
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ROX coupler implementation resulted in a signiﬁcant
reduction of 24-hour ABP in the CH group by 1420/
1410 mm Hg (both P<0.005) and in the ISH group
by 1315/119 mm Hg (both P<0.05), respectively.
In both groups, average daytime (CH: 1421/
1610 mm Hg; ISH: 1316/119 mm Hg [all
P<0.05]) and nighttime ABP (CH: 1119/1010 mm Hg;
ISH: 1214/118 mm Hg [all P<0.05]) were signiﬁ-
cantly reduced 6 months after ROX coupler implementation.
There was no difference in the reduction of 24-hour
(P=0.672/0.412), daytime (P=0.592/0.295), or nighttime
(P=0.632/0.672) systolic or diastolic ABP between the two
groups (Figure 2).
There was also no difference in the change of 24-hour
systolic ABP reduction after adjustment for baseline 24-hour
systolic ABP (P=0.695) as well as after full adjustment (sex,
age, 24-hour systolic and diastolic ABP) (P=0.940). Similar
(nonsigniﬁcant) ﬁndings were found for daytime systolic ABP
reduction (adjustment for baseline daytime systolic ABP:
P=0.765, and full adjustment [sex, age, and daytime systolic
and diastolic ABP]: P=0.940) and nighttime systolic ABP
reduction (adjustment for baseline nighttime systolic ABP:
P=0.649, and full adjustment [sex, age, and nighttime systolic
and diastolic ABP]: P=0.786).
In addition, there was no change in SBP/DBP dipping
(baseline: P=0.501/0.286; 6 months: P=0.540/0.665) as
well as dipping status between baseline and 6 months in both
subgroups (CH: P=0.705; ISH: P=0.317).
Antihypertensive Medication
There was no difference in number and type of antihyperten-
sive medication between the two groups at baseline (Table 2).
Antihypertensive medication (net effect of change) was
decreased/increased in 8/2 patients in the CH subgroup
and in 2/2 patients in the ISH group, respectively, while
antihypertensive medication remained unchanged in 28 of 42
patients during follow-up. Overall, there was no signiﬁcant
difference in (net effect of change) antihypertensive medica-
tion between the subgroups (P=0.499).
Renal Function
There was no change in eGFR between baseline and 6-month
follow-up in the two groups. eGFR changed from 79.120 to
77.621 mL/min per 1.73 m2 (P=0.420) in patients with CH
and from 67.819 to 65.216 mL/min per 1.73 m2
(P=0.234) in patients with ISH. Accordingly, no signiﬁcant
mean change in eGFR from baseline was documented between
the groups (CH: 1.510 versus ISH: 2.66 mL/min per
1.73 m2 [P=0.906]).
Figure 2. Change in systolic 24-hour, daytime, and nighttime
ambulatory blood pressure (BP) 6 months after ROX coupler
implementation in the combined hypertension group (black
columns) vs in the isolated systolic hypertension group (white
columns).
Table 2. Baseline Antihypertensive Medications of Patients
Stratiﬁed According to Subtype of Hypertension Into CH and
ISH






16 (52%) 5 (45%) 1.0000
Diuretics 28 (90%) 11 (100%) 0.5544
Thiazide 19 (61%) 6 (55%) 0.7327
Loop 7 (23%) 5 (45%) 0.2432
Aldosterone antagonist 13 (42%) 3 (27%) 0.4854
Potassium-sparing 0 (0%) 0 (0%) 1.0000
ACE inhibitors 13 (42%) 5 (45%) 1.0000
Angiotensin receptor
blockers
18 (58%) 5 (45%) 0.5038
Direct renin inhibitors 3 (10%) 0 (0%) 0.5544
b-Blockers 23 (74%) 7 (64%) 0.6992
Calcium channel blockers 24 (77%) 7 (64%) 0.4369
Dihydropyridine 20 (65%) 7 (64%) 1.0000
Nondihydropyridine 4 (13%) 0 (0%) 0.5583
a-Blockers 8 (26%) 6 (55%) 0.1358
Centrally acting
sympatholytics
5 (16%) 0 (0%) 0.3025
a-Adrenergic agonist 4 (13%) 2 (18%) 0.6437
Vasodilators 1 (3%) 0 (0%) 1.000
Nitroglycerin or nitrates 4 (13%) 0 (0%) 0.5583
Data are expressed as number (percentage) unless otherwise indicated. ACE indicates
angiotensin-converting enzyme; CH, combined hypertension; ISH, isolated systolic
hypertension.
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The main ﬁnding of our current analysis is that percutaneous
creation of a central iliac arteriovenous anastomosis reduced
ofﬁce and ABP to a similar extent in patients with CH and ISH.
The magnitude of the BP-lowering effects in patients with CH is
similar to results achieved with other interventional techniques
such as RDN. However, it was observed that in TRH patients
with ISH, BP reduction of both ofﬁce BP and 24-hour ABP after
RDN was clearly reduced in contrast to our observation
following creation of an arteriovenous anastomosis.11,12 This
discrepancy may be due to the fact that the underlying
treatment mechanism targets different pathophysiologic con-
cepts. In fact, recent expert consensus statements on RDN
noted that the failure of RDN to lower BP in some individuals
could be the consequence of arterial stiffness with subsequent
inability to dilate and decrease vascular resistance, rather than
due to technical failure of the procedure itself.16,17
From a biophysical standpoint, creating a ﬁxed-caliber
central iliac arteriovenous anastomosis adds a low-resistance,
high-compliance venous segment to the central arterial tree,
resulting in a reduction of systemic vascular resistance.18
Activation of the Frank-Starling mechanism due to increased
venous return increases cardiac output, but not commensu-
rate with the reduction of systemic vascular resistance. Most
important, the addition of a highly compliant venous parallel
compartment, compared with the chronically hypertrophied
and maximally ﬁlled arterial tree, reduces the effective arterial
blood volume. This small reduction of effective arterial blood
volume restores arterial compliance to some extent by
modulating the stress-strain curve of the aorta, which shifts
to the left with aging and in ISH.19 Improvement of structural
alterations may change the stress-strain relationship back
towards the right, resulting in increased arterial compliance
for any given BP, thereby restoring the Windkessel effect.
It is worth noting that reduction in effective arterial blood
volume is achieved without depleting the intracellular, inter-
stitial, and venous capacitance spaces, and hence without
activation of the neurohormonal system. As early as 1937,
Hallock and Benson20 analyzed the relationship between
vascular stiffness, aging, and volume expansion and were able
to demonstrate that with aging and stiffening of the arteries, a
small increase in arterial blood volume is associated with an
exaggerated increase in BP. In contrast, diuretics reduce
intracellular, interstitial, and venous capacitance volumes
before reducing effective arterial blood volume and this is
accompanied by activation of the sympathetic nervous system
and the renin-angiotensin system.21,22 In a crossover study
comprising patients with TRH, low- versus high-salt diet
resulted in a marked decrease in both ofﬁce and 24-hour ABP,
as well as a tendency toward decreased vascular stiffness.
Notably, the magnitude of BP reduction induced by sodium
restriction is substantially greater in patients with TRH than in
normotensive or (stage 1 or 2) hypertensive patients.23 These
ﬁndings support the hypothesis that in patients with TRH,
increased sodium retention (and hence intravascular volume
expansion) is a major contributor to resistance to antihyper-
tensive therapy, particularly when associated with increased
arterial stiffness.
Additional analyses strengthened the concept of compa-
rable BP reductions in patients with and without stiffened
arteries following ROX coupler implementation. Pulse pres-
sure (PP) is a valid and widely applicable proxy for arterial
stiffness.24 An ofﬁce PP >60 mm Hg in the elderly is an
acknowledged marker of target organ damage that inﬂuences
prognosis and is used for stratiﬁcation of total cardiovascular
risk.25 Dichotomization (and full adjustment) of our cohort for
PP below versus above this threshold revealed a similar BP
reduction in both subgroups (data not shown). Moreover, even
after stratifying (and full adjustment) the cohort according to
presence of marked ISH (deﬁned as 24-hour ambulatory PP
≥63 mm Hg),26,27 comparable ofﬁce BP and 24-hour ABP
reduction was evident (data not shown). Notably, only one
patient had neither an ofﬁce PP ≥60 mm Hg nor 24-hour
ambulatory PP ≥63 mm Hg, indicating that all patients were
at high cardiovascular risk.
We observed that the responder rate to coupler therapy did
not signiﬁcantly differ between patients with CH and ISH. Our
ﬁndings are also not inﬂuenced by changes in antihyperten-
sive medication. Notably, the responder rates were also
similar whether patients were stratiﬁed according to ofﬁce PP
≥60 mm Hg or 24-hour ambulatory PP ≥63 mm Hg (data not
shown).
From a clinical perspective, ISH is difﬁcult to treat with no
formal evidence-based guidance, but it is nonetheless
responsible for a substantially increased risk of cardiovascular
morbidity and mortality.28–30 The effectiveness of antihyper-
tensive medication may also be limited by vascular aging and
arterial stiffness, both known to contribute to treatment
resistance.31 Indeed, studies have consistently shown lower
rates of SBP than DBP control in patients with ISH.32,33 A
central iliac arteriovenous anastomosis may therefore offer a
new therapeutic option to treat ISH and may result in an
improvement in renal and cardiovascular outcomes.34–36
Study Limitations
Several limitations should be discussed. Our ﬁndings are
based on post hoc analyses with a small sample size, and thus
further corroboration by additional studies is required. The
ROX Control Hypertension Study was not sham-controlled,
but immediate BP reduction after arteriovenous coupler
implantation and the resulting palpable thrill in the ipsilateral
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groin may limit or even jeopardize any effect to perform a
sham-controlled randomized controlled trial. Direct parame-
ters of arterial stiffness (eg, pulse wave velocity) were not
measured, but data from a single patient undergoing central
arteriovenous anastomosis formation revealed a large reduc-
tion in pulse wave velocity (before: 15.2 versus 4 months:
13.7 m/s), which appears (partly) independent of associated
BP reduction.37 Data on cardiovascular outcome are still
lacking, but it is well known that the relative risk of
cardiovascular mortality is estimated at 2:1 (2% reduction of
mortality for each 1-mm Hg BP reduction). Further investiga-
tions are necessary, and hence the Global Registry study
(www.clinicaltrials.gov: NT1885390) was initiated to further
evaluate the ROX coupler. In addition, the consequences of
the small shunt were not elusively assessed. In one case
report, it was shown that ROX coupler implementation
resulted in an immediate as well as long-term (6-month
follow-up) reduction of systemic vascular resistance and
increment of cardiac output indicating coupler-induced
venous ﬁlling and hemodynamic unloading of the left ventri-
cle.38 Moreover, extensive experience in patients with end-
stage renal disease and similarly sized shunts for dialysis
access suggest that the risk of cardiovascular decompensa-
tion is low. In patients with end-stage renal disease, high-
output cardiac failure may occur, but volumes exceeding 30%
of cardiac output39 and ﬂow rates of at least 2.0 L/min are
necessary.40 In contrast, the ﬁxed-caliber arteriovenous
coupler permits ﬂow of only 0.8 to 1.2 L/min.15 Moreover,
arteriovenous anastomosis can be closed (with a covered
stent), if necessary, therefore eliminating its clinical risk.
Dipping status was not improved after ROX coupler imple-
mentation, which might be related to the poor reproducibility
of the classiﬁcation of patients into dippers and nondippers
over time.41,42
Conclusions
Our analyses suggest that percutaneous creation of a ﬁxed-
caliber arteriovenous anastomosis using the ROX coupler, and
therefore modifying the mechanical properties of the arterial
vascular tree, reduces ofﬁce SBP and ambulatory SBP to the
same extent in patients with CH and ISH. These data contrast
with the results of diminished BP reduction in patients with
ISH after RDN. Given the primacy of effective arterial volume
as a determinant of BP, this is perhaps not surprising and the
>90% response rate to coupler therapy observed in the ROX
Control Hypertension Study attests to this. Ongoing studies
are examining hemodynamic effects of the coupler in greater
detail and future studies should address whether patients with
TRH due to ISH would beneﬁt from treatment targeting
mechanical properties of the circulation (arteriovenous anas-
tomosis formation) as a ﬁrst choice rather than RDN.
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